Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia
- Author(s)
- Nedumannil, R; Batterham, E; Harding, E; Ritchie, D; Wei, A; Bajel, A;
- Journal Title
- Leukemia & Lymphoma
- Publication Type
- epub ahead of print
- Abstract
- High-dose cytarabine (HDAC) is conventionally delivered on days 1, 3 and 5 (HDAC-135) as acute myeloid leukemia (AML) post-remission therapy. Limited data is available on alternative HDAC schedules such as HDAC-123 (given consecutively for 3 days). We retrospectively compared the tolerability and efficacy of HDAC-135 and HDAC-123 delivered in sequential cohorts of adult AML patients. Seventy-three patients were included with 33% aged ≥60 years. HDAC-123 was associated with faster hematological recovery, reduced bacteremia and shorter hospitalization. No differences in safety profile or hematological recovery were seen between patients ≥60 years and <60 years receiving HDAC-123 except a shorter median time to neutrophil count recovery after cycle 1 in the latter group. Three patients (8%) receiving HDAC-123, all aged <60 years, required a change in schedule to HDAC-135 due to transient cytarabine-related side effects. HDAC-123 consolidation was well-tolerated by AML patients, including those ≥60 years, and associated with tangible reductions in resource utilization.
- Publisher
- Taylor & Frances
- Keywords
- Acute myeloid leukemia; consolidation chemotherapy; high-dose cytarabine; older patients
- Research Division(s)
- Blood Cells And Blood Cancer
- PubMed ID
- 37656967
- Publisher's Version
- https://doi.org/10.1080/10428194.2023.2251071
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-09-07 09:17:10
Last Modified: 2023-09-07 09:23:53